Patent · US Expired

Pharmaceutical compositions directed to Erb-B1 receptors

US7638125B2 · kind B2 · utility

0Cited by

7References

10Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Hans-Georg Kreysch · Mainz, DE
Juergen Schmidt · Goldkronach, DE

Key dates

Filing date	Oct 9, 2003
Grant date	Dec 29, 2009
Priority date	—
Expiry date	Jan 30, 2024

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S435/81
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to pharmaceutical compositions comprising different molecules, preferably monoclonal antibodies, each comprising epitopes that bind simultaneously to different sites within the same ErbB receptor domain, preferably the ErbB1 receptor domain. The preferred antibodies according to this invention are MAb 425 and MAb 225 each in its murine, chimeric and humanized version. The invention relates to the use and methods for an improved treatment of preferably tumors by means of said compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.